CAMBRIDGE, Mass.--(BUSINESS WIRE)--InVivo Therapeutics Holdings Corp. (NVIV) today announced that the University of Kansas Medical Center in Kansas City, KS has been added as a clinical site in the company’s ongoing Investigational Device Exemption (IDE) pilot study of its Neuro-Spinal Scaffold in patients with acute spinal cord injury (SCI). Paul Arnold, MD, Professor of Neurosurgery and Vice Chair of Research, has been named Principal Investigator at the site.
Help employers find you! Check out all the jobs and post your resume.
